目的 挖掘藏医治疗肝胆疾病的用药规律，寻找核心药组，并预测核心药组的潜在靶点，以探讨核心药组治疗肝胆疾病的作用机制。方法 收集藏医药典籍中治疗肝胆疾病处方，采用SPSS软件进行Apriori算法关联规则分析得到藏医治疗肝胆疾病的核心药组。检索中药系统药理学分析平台（TCMSP）、Therapeutic Target Database （TTD）、Genecards、Metascape等数据库进行基因本体（GO）和KEGG富集分析。结果 共纳入607首方剂，数据挖掘得到藏医治疗肝胆疾病的核心药组为蒂达-洪连-波棱瓜子。收集到核心药组56个活性成分，作用于47个关键靶点，预测出1194条生物过程、49个细胞组成、54个分子功能以及226条信号通路。结论 藏医在治疗肝胆疾病中主要以“清赤巴热”为核心，所使用方剂中的药物多以苦味为主；核心药组治疗肝胆疾病可能是通过缓解体内氧化应激、降低炎症表达以及调节胆汁酸肝肠循环等作用机制。

Objective To explore the law of Tibetan medicine treating liver and gallbladder diseases, look for core drug group, predict the potential targets of the core drug group, explore the mechanism action of core drug group in the treatment of liver and gallbladder diseases.Methods The prescriptions for the treatment of liver and gallbladder diseases which in Tibetan medical classical books were collected. SPSS software was used to analyze the association rules of Apriori algorithm, and eventually get the core drug groups about Tibetan medicine for the treatment of liver and gallbladder diseases. TCMSP, Symap, Genecards, TTD, Metascape and other databases were retrieved for Geneontology analysis and KEGG pathway enrichment.Results Totally 607 prescriptions were included, and the core drug group was Tida - Lagotidis Herb - Herpetospermum caudigerum. 56 active ingredients, 47 key targets with interactive relationship, 1194 biological processes, 49 cell components, 54 molecular functions and 226 pathways were collected.Conclusion Tibetan medicine in the treatment of liver and gallbladder diseases mainly focus on clear “chiba” fever. Involved drugs are mostly bitter taste; the mechanism about core group may be by relieving oxidative stress, reducing inflammatory expression and regulate the enterohepatic circulation of bile acid, so as to achieve the effect of treating liver and gallbladder diseases.